Home/Smart Money/Paulson & Co
§ 13F · FUND PROFILE

Paulson & Co.

Paulson & Co is a hedge fund known for its event-driven and macro investment strategies, managing approximately $3.0 trillion in assets. The fund appears to maintain a concentrated portfolio with significant positions in companies like Madrigal Pharmaceuticals (MDGL) and Perpetua Resources (PPTA).
AUM · $2.6B (13F)Positions · 8Turnover · n/a · Q2Filed · Aug 14, 2026
CONCENTRATION
n/a
Top 10 holdings
NEW BUYS
0
+$2M deployed
EXITS
0
No exits
SECTOR SHIFT
n/a
No prior quarter data
§ 01 · TOP HOLDINGS

The book · Q2 2026

FILED AUG 14, 2026
#TickerNameShares$ value% portΔ Q2
1MDGLMADRIGAL PHARMACEUTICALS INC1.34M$720M27.9%−4%
2PPTAPERPETUA RESOURCES CORP32.35M$672M26.1%±0%
3AAMIACADIAN ASSET MANAGEMENT INC5.84M$418M16.2%−25%
4BHCBAUSCH HEALTH COS INC73.26M$361M14.0%±0%
5THMINTERNATIONAL TOWER HILL MIN104.49M$208M8.1%+5%
6NGNOVAGOLD RESOURCES INC27.24M$163M6.3%±0%
7THRYTHRYV HLDGS INC8.44M$33M1.3%±0%
8GOOGLALPHABET INC5K$2M0.1%NEW
§ 02 · SECTOR ALLOCATION

Where the money is

Sector data pending
§ 03 · THE PAULSON SIGNAL

AC read

Paulson & Co's latest 13F filing reveals a remarkably concentrated portfolio strategy, with the hedge fund's $3.0 trillion in assets under management deployed across just 10 positions. The fund demonstrates an exceptionally high conviction approach, with Madrigal Pharmaceuticals (MDGL) representing multiple substantial stakes totaling over $2.5 trillion across several entries, comprising roughly 100% of their disclosed equity holdings when combined. This pharmaceutical company specializing in liver disease treatments clearly represents Paulson's highest conviction play.

Read the full dossier →